Jeffrey Quillen, co-chair of Foley Hoag's Life Sciences Industry Group, will join a panel discussion on "The Venture Investor Outlook and Investing in the Therapies of Tomorrow" during the LSX World Congress USA, a gathering of 1000+ leaders and featuring key trends and best practices for issues affecting the U.S. biotech, medtech and healthtech sectors.
While the funding environment remains challenging for some, the enthusiasm and belief in continued investments by VC in novel technology platforms and innovative assets is inspiring. Jeff's panel will take a deeper dive into the investment landscape with some of the industries leading investors for discussions on:
- the current 2024 outlook for biotech investment
- critical forces impacting biotech over the next 12 months
- alternative methods to fundraise
- how investors are viewing late-stage vs early-stage biotechs
